Research Article
Chemosensitivity of Anaplastic Thyroid Cancer Based on a Histoculture Drug Response Assay
Table 1
Summary of 22 cases of ATC.
| | Cases | Age (y)/sex | Site | Curability | Induction PTX | HDRA (1) (%) | Adjuvant PTX | HDRA (2) (%) | PFS | Survival | OS |
| | 1 | 70/F | Primary | Curative | No | 83.9 | 9 | NA | 3 M (local) | Died | 6 M | | 2 | 68/F | Primary | Curative | No | 0 | 7 (PD) | NA | 1 M (lung) | Died | 7 M | | 3 | 59/M | Local LN | Curative | No | 79.4 | 16 | NA | >52 M (DF) | Alive | >52 M | | 4 | 83/F | Primary | Curative | 3 (SD) | 84.5 | 12 | 84.5 (lung) | 5 M (lung) | Died | 32 M | | 5 | 80/M | Primary | Noncurative | 5 (SD) | 84.3 | 12 (CR) | NA | 9 M (brain) | Died | 14 M | | 6 | 71/F | Primary | Curative | 6 (SD) | 71.1 | 5 (PD) | NA | 3 M (local) | Died | 4 M | | 7 | 75/F | Chest wall | Noncurative | No | 81.4 | No | NA | 0 M | Died | 0 M | | 8 | 65/F | Primary | Curative | No | 83.0 | 16 | NA | 10 M (lung) | Died | 16 M | | 9 | 70/F | Axillary LN | Noncurative | No | 84.7 | No | 84.2 (local LN) | 3 M (local) | Died | 8 M | | 10 | 82/F | Primary | Curative | 7 (SD-PR) | 52.3 | 6 (PD) | NA | 5 M (local, lung) | Died | 7 M | | 11 | 59/M | Primary | Curative | 8 (PR) | 84.7 | 8 (PD) | NA | 5 M (local, lung) | Died | 14 M | | 12 | 71/M | Primary | Curative | 7 (SD-PR) | 77.8 | 7 (PD) | 79.5 (local LN) | 3 M (local, lung) | Died | 7 M | | 13 | 62/F | Local rec. | Noncurative | No | 75.1 | 12 (PD) | 67.7 (local rec.) | 5 M (local) | Died | 11 M | | 14 | 86/M | Primary | Noncurative | No | 77.9 | No | NA | 1 M (bone) | Died | 12 M | | 15 | 63/F | Local rec. | Noncurative | 4 (PD) | 82.3 | 17 (SD-PD) | 76.4 (local rec.) | 3 M (local, lung) | Died | 12 M | | 16 | 59/F | Primary | Noncurative | 6 (PR) | 84.2 | 10 (PD) | 82.9 (lung) | 4 M (lung) | Died | 7 M | | 17 | 81/F | Primary | Curative | 8 (PR) | 87.2 | 4 | NA | >17 M (DF) | Alive | >17 M | | 18 | 76/F | Primary | Curative | 6 (SD) | 81.5 | 7 | 79.6 (local rec.) | 3 M (local) | Died | 4 M | | 19 | 63/F | Primary | Curative | 5 (CR) | 58.4 | 7 | NA | >16 M (DF) | Alive | >16 M | | 20 | 47/F | Primary | Curative | 10 (SD) | 76.2 | 6 | NA | >9 M (DF) | Alive | >9 M | | 21 | 71/F | Primary | Curative | 8 (SD-PR) | 87.2 | 3 (PD) | NA | 4 M (local) | Died | 4 M | | 22 | 79/F | Primary | Curative | No | 82.4 | 12 | NA | 6 M (lung) | Alive | >7 M |
|
|
Curability: surgical curability of operation, induction PTX: preoperative treatment by weekly paclitaxel, adjuvant PTX: postoperative treatment by weekly paclitaxel, HDRA (1): induction rates of the samples at the initial surgery with 40 μg/mL PTX, HDRA (2): induction rates of relapsed lesions with 40 μg/mL PTX, OS: overall survival, LN: lymph node, rec.: recurrence, DF: disease-free, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, F: female, and M: male.
|
